Clinical trial
A Randomized Controlled Comparison of Hepatic Directed Vesicle (HDV)-Insulin Lispro Versus Insulin Lispro Alone to Further Improve Glycemic Control in Type 1 Diabetes Mellitus Subjects With Good Glycemic Control
NCT03096392 is registered in ClinicalTrials.gov with Diasome Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Controlled Comparison of Hepatic Directed Vesicle (HDV)-Insulin Lispro Versus Insulin Lispro Alone to Further Improve Glycemic Control in Type 1 Diabetes Mellitus Subjects With Good Glycemic Control
- Lead sponsor
- Diasome Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- April 18, 2017
- Completion date
- March 18, 2018
- Enrollment
- 46 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.